Aarti Pharmalabs uploads Q4FY26 earnings call recording
Aarti Pharmalabs Limited has uploaded the audio recording of its earnings conference call for the fourth quarter and financial year ended March 31, 2026. The disclosure, compliant with Regulation 30 of the SEBI (LODR) Regulations, 2015, allows stakeholders to access management commentary on the company's performance via a link on its official website.
*this image is generated using AI for illustrative purposes only.
Aarti Pharmalabs Limited has uploaded the audio recording of its earnings conference call discussing the audited financial results for the fourth quarter and financial year ended March 31, 2026. The recording is now available on the company's website, providing access to the management's commentary on the performance for Q4FY26. This disclosure was made in accordance with Regulation 30 of the SEBI (LODR) Regulations, 2015.
The conference call was initially scheduled for May 26, 2026, to review the company's financial outcomes for the period. Key executives, including the Chairman, Vice Chairperson and Managing Director, and the Chief Financial Officer, had participated in the discussion to address investor and analyst queries regarding the quarterly and annual performance.
Accessing the Recording
Stakeholders who missed the live event or wish to revisit the discussion can now access the audio file online. The company has provided a direct link to the recording on its official portal.
| Detail | Information |
|---|---|
| Event | Earnings Conference Call Recording |
| Period | Q4 and FY ended March 31, 2026 |
| Access Link | Aarti Pharmalabs Website |
For further details, participants may refer to the company's official communication or contact the investor relations cell.
Historical Stock Returns for Aarti Pharma Labs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.34% | +3.41% | -8.83% | -12.25% | -29.24% | +125.41% |
What are the key growth drivers Aarti Pharmalabs anticipates for the upcoming fiscal year following the Q4FY26 performance?
How does the company plan to navigate potential regulatory changes in the pharmaceutical sector over the next 12 months?
What strategic capital allocation priorities did management highlight during the call for FY27?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
